Aptus Pharma reported a significant surge in H1 FY2027 performance, with revenue climbing to Rs 48.92 crore and net profit reaching Rs 5.08 crore. The company also disclosed progress on a Rs 44.88 crore preferential share issue, pending BSE approval, to fuel its national expansion plans.
Aptus Pharma Reports Strong H1 Performance and Capital Expansion Plans
Revenue reached Rs 48.92 crore, while net profit (PAT) grew to Rs 5.08 crore for the half-year ended September 30, 2026.
Reader Takeaway: Robust year-on-year growth trajectory contrasts with the pending status of the company’s Rs 44.88 crore capital infusion plan.
What just happened
Aptus Pharma announced its unaudited financial results for the half-year ending September 30, 2026. Revenue grew to Rs 48.92 crore from Rs 14.38 crore in the same period last year. Profit after tax rose to Rs 5.08 crore, up from Rs 1.75 crore. The company confirmed these figures include adjustments for a 3:2 bonus issue conducted in May 2026. Simultaneously, the company is moving forward with a preferential issue of 1,602,870 shares at Rs 280 each, totaling Rs 44.88 crore, currently awaiting BSE in-principle approval.
Why this matters
The financial results signal strong operational momentum, with a significant jump in both top-line and bottom-line figures. The proposed preferential issue is a critical pillar for the company’s stated goal of transitioning into a national pharmaceutical player, as the funds are intended to support infrastructure and distribution network expansion.
The backstory
At the AGM on September 14, 2026, shareholders authorized the preferential issue. As of October 20, 2026, the company has not received application money nor allotted the shares, meaning these figures are not yet reflected in the current balance sheet.
What changes now
Management has outlined a strategy to increase geographic coverage to 46% across India by March 2027. Investors should monitor the regulatory approval process with the BSE, as this will trigger the formal capital infusion and share allotment.
Risks to watch
The primary risk is regulatory delay; until the BSE grants in-principle approval, the capital infusion remains a proposal rather than a completed transaction. Any extended delay could impact the company’s ability to meet its aggressive geographic expansion timeline.
What to track next
Watch for the official communication regarding the receipt of BSE in-principle approval and the subsequent allotment of shares to the identified investors.